Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Public Storage — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.38 (market cap $29.60B), while Public Storage trades at $325.23 (market cap $60.71B). The key difference: Public Storage is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Public Storage pays a 3.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PSA | |
|---|---|---|
Market Cap | $29.60B | $60.71B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $330.47 |
52-Week Low | $205.48 | $258.44 |
Enterprise Value | $27.56B | $74.98B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Public Storage (PSA) trades at $325.71, down 0.82% on the day, with a bullish technical outlook supported by moving averages. The REIT maintains strong profitability with 41.8% net income margin and has beaten earnings estimates for three consecutive quarters. Recent developments include the completed acquisition of National Storage Affiliates and consistent $3.00 quarterly dividends, positioning the company for growth through expansion and operational efficiency.
PSA presents a mixed investment case with premium valuation metrics (P/E 31.02) offset by strong fundamentals and growth initiatives. The consensus price target of $333.88 suggests modest upside potential, though elevated P/E and P/B ratios warrant caution. Key risks include interest rate sensitivity and integration challenges from recent acquisitions, while the stable dividend and expansion into Canada provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
